Business
BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium
BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 Inte...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, June 27, 2018\n\n\n\n- Preclinical Data Highlights BLU-5937 as a Potential Best-In-Class Treatment for Chronic Cough -- First In-Human Study to Begin in July 2018 - \n\n\n\nLAVAL, QC, June 27, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) (\"BELLUS Health\" or the \"Company\"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today presented preclinical data on its lead drug candidate, BLU-5937 for the treatment of chronic cough. Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, provided a review of the data at the 2018 International Cough Symposium in London, UK. In summary, animal studies demonstrated that BLU-5937 is a highly selective P2X3 antagonist exhibiting a potent anti-tussive effect without affecting taste perception. The preclinical toxicology studies also demonstrated an excellent safety profile for BLU-5937.\n\nThe Company also updated the timeline for the initiation of its first in-human study for BLU-5937 to July 2018. The main objectives of the Phase 1 clinical study will be to assess the safety, tolerability (including taste perception) and pharmacokinetic profile of BLU-5937 in healthy subjects.\n\n\"The results of our preclinical studies demonstrate that BLU-5937 selectively targets the receptors that have been shown to play a major role in the cough reflex, leading to a significant reduction in cough frequency without affecting taste,\" said Dr. Denis Garceau, Senior Vice President of BELLUS Health. \"We are poised to begin in the coming weeks our first in-human study for BLU-5937 and are looking forward to reporting the results in the fourth quarter of 2018.\" \n\nHighlights of the Presentation\n\n\nP2X3 receptors are known to assemble and function as P2X3 homotrimer or P2X2/3 heterotrimer structures. Histological, immunochemis...